Myosin VI, encoded by MYH6, is expressed dominantly in human cardiac atria and plays consequential roles in cardiac muscle contraction and comprising the cardiac muscle thick filament. Mutations in the MYH6 gene associated with Atrial septal defect type 3 (ASD3), hypertrophic (HCM) and dilated (DCM) cardiomyopathies.
Methods and Results
Two patients in an Iranian family have been identified who affected to Congenital Heart Disease (CHD), ASD, thyroglossal sinus, refractive errors of the eye and meatal stenosis. The first symptoms emerged at the birth and diagnosis based on clinical features was made at 5 years. The family had a history of cardiomyopathy. For recognizing mutated gene(s), whole exome sequencing (WES) was performed for the patient and variants were analyzed by autosomal dominant inheritance model. Eventually, by several filtering processes, a novel mutation in MYH6 gene (NM_002471.3), c.3835C>T; R1279X, was identified as the most likely disease-susceptibility variant and then confirmed by Sanger sequencing in the family. This mutation results in the elimination of the 660 amino acids in the C-terminal of Myosin VI protein, including the vital parts of the coiled-coil structure of the tail domain.
Our data indicate that c.3835C>T mutation in MYH6 gene is associated with cardiac malformation and probably has a destructive role in heart development. It is the first case of ASD type 3 that caused directly by MYH6 nonsynonymous mutation.
Keywords: MYH6; Congenital Heart Disease (CHD); ASD; Nonsense mutation; WES
Running Title: MYH6 mutation and CHD Disease
Congenital Heart Defects (CHDs) are one of the major causes of death due to congenital malformations and show some of the more preponderant malformations among live births. It has been revealed that both familial and sporadic forms of CHDs result from mutations in several genes based on human cases and animal models (1). Based on targeted deletions studies in mice, it has been suggested that there are more than five hundred genes involved in heart disorders (Mouse Genome Informatics (http://www.informatics.jax.org)) (2). CHDs treat greatly as a complex trait and to date, the number of familial cases has distinguished by the Mendelian segregation of single-gene mutations are so few (3).
Both inherited and non-inherited factors account for congenital heart disease (CHD). The incidence of CHD approximately is 0.4-0.6% live births and real prevalence is about 4% (4, 5). Our knowledge about CHD’s causes and mechanisms remains restricted in spite of the advances in diagnosis and interventions. With development of whole exome/genome sequencing more CHD causing genes possibly will be clarified which will increase our insight into the genetic causes of CHD.
Numerous epidemiological studies have suggested a genetic component of CHD etiology. Approximately, 25 percent of CHD cases occur as a complex trait with related defects in other organs as a sporadic malformative association, Mendelian syndrome or chromosomal abnormality (6). The rest of cases occur as isolated defects and both sporadic and familial cases that showing Mendelian patterns of inheritance, have been reported (7, 8). To date, several diseases associated with MYH6 mutations such as hypertrophic (HCM), dilated cardiomyopathy (DCM) and atrial septal defect (ASD) have been reported (9). ASD is categorized as the second most common CHD and accounts for 10% of all cardiac malformations (10). Around 80% of persistent small ASDs close spontaneously during infancy or childhood, but the large one could cause serious defects such as congestive heart failure, pulmonary vascular disease and etc. (11). There are various types of ASD. ASD type 3 is caused by mutations in MYH6 (12). It has not been identified any correlation between the nonsynonymous mutation of MYH6 and ASD3 but in the present study, we could detect this correlation.
In the present study, we checked out a clinically characterized family with a history of congenital heart disease. In this family, we observed an obvious autosomal-dominant inheritance with reduced penetrance (K=50%). We identified a novel nonsense mutation in MYH6, NM_002471.3 c.3835C>T; R1279X, by WES of the patient and his parents in the SH1190831 family and then this mutation was confirmed by Sanger sequencing.
Material and Methods
Patients and clinical evaluations
The study protocol was approved by the local medical ethics committee of Tarbiat Modares University, Tehran, Iran. Informed consents were obtained from all individuals. All of the patient’s clinical information and the medical histories were collected at the Department of Medical Genetics, DeNA Laboratory, Tehran, Iran.
We enrolled 5 members of this family in our study (two affected, two unaffected and one carrier) (Table 1). Subjects were adjusted by meticulous medical records including a complete physical examination, a 12-lead Echocardiogram (ECG), Ultrasonic cardiogram (UCG) and other relevant features such as PR, QRS interval, QT, QTc duration and QRS axis were measured. QRS axis was presumed as normal when its value was measured between-30? and +90? and was classified abnormal when out of this range. The normal range of ECG was performed based on the individual ages. For adults, a PR interval above 210 ms and an increased above 100 ms of QRS interval were thought-out prolonged (13).
Genomic DNA was isolated from peripheral blood of the family members by the ROCHE DNA Extraction Kit (Cat. No. 11814770001).
Exome capturing and high throughput sequencing (HTS) was performed on the proband (III:1) and his parents. The Nextera Rapid Capture Exome kit with 340,000 probes designed against the human genome was utilized to enrich the approximately 37 Mb (214,405 exons) of the Consensus Coding Sequences (CCS) from fragmented genomic DNA. Due to limitations of the method, not all exons were fully covered and all of the pathogenic variants cannot be totally excluded. An overall coverage of 98.19% was achieved, with 2188 missing base pairs (a coding region including ± 2bp). At the next step, an end to end in-house bioinformatics pipelines including base calling, primary filtering of low-quality reads and probable artifacts, and annotation of variants were applied.
The reads were aligned to the NCBI human reference genome (gh19/NCBI37.1) with SNP & Variation Suite version 8.0 (SVS v8.0) and DNASTAR Lasergene12 (DNASTAR Inc., Madison, Wisconsin USA). Small indel detection was used with the Unified Genotyper tool from GATK tools in Galaxy online database (http://www.usegalaxy.org). The missense, nonsense, silent, and indel mutations rates were estimated by Galaxy online tool and finally were confirmed by Ivariantguide® (https://www.advaitabio.com).
Several filtering steps were applied to prioritize all variants: 1) Variants in dbSNP132 (https://www.ncbi.nlm.nih.gov/projects/SNP) and 1000 Genomes Project (http://www.1000genomes.org) with allele frequencies more than 1% were excluded. 2) The rest of variants underwent further exclusion in Exome Sequencing Project (ESP) (http://evs.gs.washington.edu/EVS) and Exome Aggregation Consortium (ExAC) database. 3) The intragenic, intronic, UTRs regions and synonymous variants were excluded from later analysis. 4) The SIFT (http://sift.jcvi.org/), Provean (http://provean.jcvi.org) and Mutation Taster (http://www.mutationtaster.org) were used to predict variants pathogenicity (Table 3).
All suspected pathogenic variants were checked out in HGMD (http://www.hgmd.cf.ac.uk) and ClinVar (https://www.ncbi.nlm.nih.gov/clinvar). Finally, based on family pedigree, autosomal dominant inheritance pattern and clinical information were used to evaluate identified variants. Based on the clinical information, specific attention has been paid to the 42 genes known for Arrhythmogenic Cardiomyopathy, HCM, and DCM. Eventually, we identified a novel nonsense mutation in MYH6 (NM_002471.3, c.3835C>T, R1279X) that can play a destructive role in the function of the tail domain in Myosin VI protein. Also, ConSurf (http://www.consurf.tau.ac.il) was applied to provide evolutionary conservation profile for Myosin VII protein and showing the staple role of the novel mutation (Figure 2.C).
Mutation Validation and Co-Segregation Analysis
Sanger sequencing in forwarding and reverse directions was performed to validate the candidate variants found in WES and then segregation analyses were performed in the family. The primers were designed by Primer3.0 (http://bioinfo.ut.ee/primer3-0.4.0) web-based server (Table 2). We checked out the lack of SNPs in the genomic region corresponding to the 3? ends of primers by looking through the dbSNP database. The primers specificity was checked by the in-silico-PCR tool in UCSC genome browser and Primer blast of NCBI genome browser and finally, the PCR was utilized in standard conditions and samples were sent to Sanger sequencing.
We identified an Iranian family affected by multiple complex phenotypes ranging from CHD, atrial septal defect (ASD), thyroglossal sinus to refractive errors of the eye and meatal stenosis. The proband (III.1), a 14-year male, affected with ASD and Thyroglossal sinus. Both parents were assessed for the relevant clinical features but we could not detect any relevant symptoms. Physical examination demonstrated ASD in the patient (Table 1). The family history examination clarified that the patient II2 has the same condition. The II.4 sample, in spite of carrying the mutation, indicated no obvious phenotype implying the reduced penetrance in this condition.
All family members were recruited for further physical examination and all gathered records have been reported in table 1.
It is postulated that the pedigree may represent an autosomal dominant inheritance with reduced penetrance. To elucidate the underlying genetic cause(s), genomic DNA was obtained from the patient and analyzed by whole exome sequencing (WES). The novel mutation was confirmed by Sanger sequencing (Figure 1.B).
The detected SNVs and deletion/insertions were analyzed by several filtering methods. 66109 variants were found in the exome of the proband after alignment and SNV calling. After several exclusion processes by using of dbSNP132, 1000 Genomes Project, Exon Sequencing Project (ESP), and ExAc databases, thirteen variants were identified and then prioritized by patients’ phenotype. Eventually, tally with the patient’s phenotypes, a novel variant was identified that shared by two affected and one carrier family members (II2, III1, II4) but not observed in other healthy parent or normal control (II5).
In the same statement, of the 1187 variants, 13 were ranked using three database tools (Provean, Mutation Taster, Sift) and finally, among the thirteen variants, a unique variant was opted as a pathogenic mutation of this unique family based on patient’s phenotype by utilizing CentoMD (https://www.centogene.com) and ClinVar. (https://www.ncbi.nlm.nih.gov/clinvar/) (Figure 1.C).
Samples from the available members of the SH1190831 family were subjected to Sanger sequencing to confirm the candidate variant of MYH6 gene. The polymerase chain reaction (PCR) products were sequenced by ABI 730XL, using the conventional capillary system, and then the Sequences were analyzed by Genome Compiler online tool to identify the alternations.
To find the main cause of CHD in the proband by known genetic mutation(s), based on proband phenotype, we especially focused on the 42 genes that have critical roles in CHD etiology and revised our strategies with a filter of pertinent variants in these genes (Supplementary Table 1). The single patient analysis excluded the possibility of a known causative gene that underlies CHD.
Atrial septal defects (ASD) belong to a group of CHD that allow communication between the left and right sides of the heart although the communications include several distinct defects in the cardiac terminations of the pulmonary veins (sinus venosus and coronary sinus defects) and in the interatrial septum (atrial septal defects). ASDs, based on the defected gene, have been classified into several groups. The mutations in various genes have been associated with atrial septal defects, for instance, mutations in NKX2-5, GATA4 and TBX5, and MYH6 (14).
It has been identified that there are at least 35 classes of molecular motors into the myosin superfamily that move along actin filaments (15). Several studies have described various functions for Myosin VI such as membrane trafficking, endocytosis, organizing and stabilizing the actin cytoskeleton and playing a material role in inner-ear hair cells (16-18). Myosin VI is the merely class of myosin that known to move toward the minus-end of actin filaments. Intuitively, dimerization of the myosin can expand its movement along actin filament but it must be noticed that the Myosin VI does not contain a well-defined coiled-coil dimerization domain, suggesting that myosin-VI does not form a constitutive dimer on its own. The MYH6 gene encodes Myosin heavy chain, ? isoform (MHC-?) in human Myosin VI (19). This protein has several important domains such as head domain, IQ domain, cargo-binding domain, tail domain and etc. (Figure 2). The tail domain involves two distinct section: Coiled-coil domain and globular domain. It has been identified that the tail domain has a staple role in interacting with the target, especially uncoated vesicles (20).
NGS and particularly whole exome sequencing techniques have been developed into a robust and cost-effective tool to identify the new variants or genes for rare Mendelian unknown disorders (21-23). This technique has been used in genetic diagnostics helping to increase the clinical and mutational spectrum of known and unknown diseases (24, 25). But sometimes it is so difficult to distinguish between pathogenic and benign mutations (26, 27). Several filtering strategies have been developed to exclude variants that are implausible to cause disease.
In this study, we utilized the WES technique to identify a novel nonsense mutation at codon 3825 of MYH6 gene. This mutation is located at the extremely conserved region in MYH6, Myosin heavy chain-? isoform (MHC-?), and it is presumed to result in a truncated protein that is associated with Cardiomyopathy and ASD type 3 (OMIM: 614089, 613251). Previously, it has been reported that the mutations in MYH6 are associated with late-onset hypertrophic cardiomyopathy, atrial septal defects and sick sinus syndrome (13, 28). There are numerous reports on the association of MYH6 mutations and CHD (29).
In the present study, we identified a novel nonsense variant, c.3835C>T, R1279X, by whole exome sequencing in the coiled-coil region or tail domain of MYH6 gene. This region mediates interaction with cargo molecules or other myosin subunits. After several staple filtering and annotation processes, to predict whether the novel variant was deleterious or not, we utilized several databases such as SIFT, Mutation Taster, and Provean. We also analyzed intronic, synonymous, nonsense, missense and frameshift indel changes to predict whether those changes could affect splicing process by influencing on donor or acceptor splice sites, with mutation taster and Neutral Network Splice (NNSplice version 0.9).
Our result indicates that this nonsense mutation (R1279X) in MYH6 might be the genetic cause of congenital heart disease. Our study confirms that the MYH6 gene has an important role in heart functions but we recommend the applying animal modeling to scrutinize the distinctive role of this mutation.
For first time, we identified a novel nonsense mutation, c.3835C>T, R1279X, in MYH6 gene as a possible cause of CHD in an Iranian family. This finding will increase our knowledge about the etiology of this rare condition by effective clarification of the causative gene mutations and will enhance the mutational spectrum of CHD and should consider in the diagnosis of these diseases.
We thank the family for their participation in this study. We are especially grateful to the staffs of DeNA laboratory for helping us in this research and additionally, we appreciate supports from Dr. Elika Esmaeilzadeh and Dr.Farveh Ehya, Tarbiat Modares University, Tehran, Iran. This research received no specific grant from any funding agency, commercial or not for profit sectors.
Conflict of Interest
The authors report no conflicts of interest.